LINC01405: A Drug Target / Disease Biomarker (G100131138)

Target Name: LINC01405

NCBI ID: G100131138

LINC01405

Other Name(s): long intergenic non-protein coding RNA 1405 | Long intergenic non-protein coding RNA 1405

LINC01405: A Drug Target / Disease Biomarker

LINC01405 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and muscle. It is a key regulator of cell adhesion and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of LINC01405 is its potential as a drug target. LINC01405 has been shown to interact with a wide range of molecules, including G protein-coupled receptors (GPCRs), which are a family of transmembrane proteins that play a key role in cellular signaling.

GPCRs are involved in many important physiological processes in the body, including sensory perception, neurotransmission, and hormone signaling. They are also frequently mutated in a variety of diseases, including cancer and neurodegenerative disorders. As a result, GPCRs make an attractive target for drug development, as drugs that interact with them can have a wide range of effects depending on the specific GPCR they interact with.

One of the challenges in developing a drug that interacts with LINC01405 is that the protein is expressed in many different tissues and organs, making it difficult to predict where it will be most effective. However, recent studies have identified a number of potential drug targets for LINC01405 that may be able to interact with the protein in different tissues.

One potential drug target for LINC01405 is the protein known as FAK, which is involved in cell adhesion and has been implicated in many diseases, including cancer. FAK is a GPCR that is highly expressed in various tissues, including the brain, and has been shown to interact with LINC01405 in a number of ways.

FAK has been shown to promote the formation of tight junctions, which are a type of cell-cell adhesion that is critical for maintaining tissue structure and function. It has also been shown to play a role in the regulation of cell proliferation and the development of cancer. As a result, LINC01405 and FAK may be a good candidate for a drug that targets FAK and inhibits its activity.

Another potential drug target for LINC01405 is the protein known as PDGF-尾, which is involved in cell signaling and has been shown to play a role in many diseases, including cancer. PDGF-尾 is a GPCR that is highly expressed in various tissues, including the liver, and has been shown to interact with LINC01405 in a number of ways.

PDGF-尾 has been shown to promote the formation of blood-brain barrier (BBB) structures, which are specialized barriers that protect the brain from foreign substances. It has also been shown to play a role in the regulation of cell proliferation and the development of cancer. As a result, LINC01405 and PDGF-尾 may be a good candidate for a drug that targets PDGF-尾 and inhibits its activity.

In addition to FAK and PDGF-尾, there are many other potential drug targets for LINC01405 that have been identified in recent years. These include proteins involved in cell signaling, cell adhesion, and inflammation. As more research is done on LINC01405 and its potential drug targets, it is likely that new targets will be identified that can further our understanding of the protein and its role in various diseases.

Overall, LINC01405 is a protein that is highly expressed in various tissues and has been implicated in a number of diseases. Its potential as a drug target is currently being investigated by researchers, with a focus on GPCRs, FAK, and PDGF-尾. As more research is done on LINC01405 and its potential drug targets, it is likely that new treatments will be developed that can help to improve the health and well-being of individuals with these conditions.

Protein Name: Long Intergenic Non-protein Coding RNA 1405

The "LINC01405 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01405 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets